CFO
TLX

CVA Family Office’s Telix Pharmaceuticals TLX Stock Holding History

CVA Family Office’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22K Buy
+127
New +$967 ﹤0.01% 1619

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

CVA Family Office's TLX Position: Q1 2026 in Review

CVA Family Office opened a new position in Telix Pharmaceuticals (TLX) in Q1 2026: 127 shares worth $1.22K. The stake represents ﹤0.01% of the portfolio and ranks #1619 among its holdings.

39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • CVA Family Office held 127 shares of Telix Pharmaceuticals worth $1.22K as of Q1 2026.
  • Telix Pharmaceuticals was a new CVA Family Office position in Q1 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1619 holding.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.